Recently, a multi-targeting treatment strategy was devised to target MAO-B and AChE, and it has been reported that MAO and AChE inhibitors can improve the cognitive functions and relieve symptoms in AD by increasing monoamine and choline ester levels9. This evidence concerns the gene MAOB and Alzheimer disease.